Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Clearside Biomedical EBITDA Margin % Related Terms
Clearside Biomedical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Clearside Biomedical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CLM0 vs LYRA, EVFM, ATXI: EBITDA Margin % Comparison
For the Biotechnology subindustry, Clearside Biomedical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearside Biomedical EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearside Biomedical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Clearside Biomedical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical (STU:CLM0) has a EBITDA Margin % of -1,653.22% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clearside Biomedical and its competitors. According to the industry distribution chart, Clearside Biomedical ranks #657 out of 940 companies in the Biotechnology industry, placing it in the top 69.9%.
Is Clearside Biomedical's EBITDA Margin % too high?
Clearside Biomedical's current EBITDA Margin % is -1,653.22%. Based on the distribution chart, Clearside Biomedical ranks #657 out of 940 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Clearside Biomedical has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's EBITDA Margin % compare to LYRA and EVFM?
According to the Biotechnology industry distribution chart, Clearside Biomedical ranks #657 out of 940 companies for EBITDA Margin %. This places Clearside Biomedical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clearside Biomedical and its competitors. Clearside Biomedical's current EBITDA Margin % is -1,653.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Clearside Biomedical (STU:CLM0) has a current EBITDA Margin % of -1,653.22%. The stock's GF Value™ is €110.06, compared to a current price of €4.35 — trading 96% below its estimated fair value. The current EBITDA Margin % is -1,653.22%. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Clearside Biomedical (STU:CLM0), the current EBITDA Margin % is -1,653.22% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clearside Biomedical (STU:CLM0) Overvalued in 2026?
Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued.
The current stock price of €4.35 is trading 96% below its estimated GF Value™ of €110.06.
Key valuation signals for STU:CLM0:
EBITDA Margin %: -1,653.22%
GF Value™: €110.06 vs. price of €4.35 (96% below fair value)
No single metric tells the full story. See the STU:CLM0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score
Get the complete analysis for STU:CLM0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CLM0 has been successfully added to your 
